ZOM (ZOM)
Zomedica Corp.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Rowe Jeffrey M | Director | Purchase | 100.6K | $7.0K | Mar 17, 2025 |
 MACLEOD CHRISTOPHER ROSS | Director | Purchase | 143.0K | $8.4K | Mar 17, 2025 |
 POWERS JOHNNY D | Director | Purchase | 100.0K | $6.9K | Mar 17, 2025 |
| POWERS JOHNNY D | Director | Purchase | 50.0K | $3.5K | Mar 17, 2025 |
| POWERS JOHNNY D | Director | Purchase | 100.0K | $6.7K | Mar 17, 2025 |
| POWERS JOHNNY D | Director | Purchase | 100.0K | $6.7K | Mar 17, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
 Klass Russell Kevin Sr Vice President, Sales | 6.0M | -- | FORM 4 |
 POWERS JOHNNY D Director | 4.4M | -- | FORM 4 |
 HEATON LARRY C II CEO, Director | 1.3M | -- | FORM 4 |
 Blair Anthony K COO | 1.0M | -- | FORM 4 |
 Jordan Scott Chief Financial Officer | 300.0K | -- | FORM 4 |
 Williams Rodney James Director | 261.9K | -- | FORM 4 |
 MACLEOD CHRISTOPHER ROSS Director | 143.0K | -- | FORM 4 |
 DeHaan-Fullerton Karen General Counsel | 104.3K | -- | FORM 4 |
Ancora Advisors LLC | 83.6K | -- | 13F |
CoreCap Advisors, LLC | 4.8K | -- | 13F |
Insiders
- Rowe Jeffrey MDirector
- MACLEOD CHRISTOPHER ROSSDirector
- POWERS JOHNNY DDirector
- HEATON LARRY C IICEO
- Blair Anthony KCOO
- Klass Russell KevinSr Vice President, Sales
- Williams Rodney JamesDirector
- Jordan ScottChief Financial Officer
- Cohen RobertDirector
- DeHaan-Fullerton KarenGeneral Counsel
Zomedica Corp. is a veterinary healthcare enterprise dedicated to fulfilling the specific needs of clinical veterinarians through the creation of products for companion animals.
The company is actively involved in the development and market introduction of its TRUFORMA platform, which delivers point-of-care diagnostic tools for various canine and feline illnesses.
Additionally, Zomedica provides PulseVet, a system used to address a range of musculoskeletal conditions such as fractures, tendonitis, and torn ligaments in horses and smaller animals. Zomedica also maintains collaborative agreements, including one with Celsee, Inc. for the joint development and commercialization of liquid biopsy assays and consumables for detecting cancer in pets, and another with Seraph Biosciences, Inc. for the development and marketing of a novel pathogen detection system. Established in 2015 and based in Ann Arbor, Michigan, the company was formerly known as Zomedica Pharmaceuticals Corp. before adopting its current name in October 2020.
US30d Avg
--
60d Avg
--
90d Avg
--